Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group B recombinant lipoprotein 2086 vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
A recombinant protein vaccine developed for the prevention of invasive disease caused by *Neisseria meningitidis* serogroup B. It contains two recombinant lipidated factor H binding proteins (fHBP) from divergent serogroup B strains. Its mechanism relies on eliciting immune responses that generate bactericidal antibodies against meningococcal serogroup B, preventing severe conditions like meningitis and sepsis. The vaccine is indicated primarily for adolescents and young adults at high risk of exposure or during outbreaks. It is not expected to protect against serogroups other than B.
- Brand names
- Trumenba
- Other names
- meningococcal group B rLP2086 vaccinemeningococcal group B recombinant lipoprotein 2086 vaccinerLP2086 vaccinerLP-2086 vaccinerLP 2086 vaccinebivalent recombinant LP2086Trumenba
02
Targets
Factor H-binding protein subfamily AFactor H-binding protein (fHbp) subfamily BCFH (Complement factor H)fHbp (Factor H-binding protein)
Beyond the preview
Go deeper on meningococcal group B recombinant lipoprotein 2086 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group B recombinant lipoprotein 2086 vaccine.